Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075820 | 0.79 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL3074959 | 0.78 | MAOA (0.50) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL574574 | 0.77 | MAOA (0.48) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL584704 | 0.75 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL1491183 | 0.75 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL15284925 | 0.75 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL2596861 | 0.75 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL1871104 | 0.75 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL5181287 | 0.75 | MAOA (0.46) | MAOAMAOBOXTRABCG2ITGB2 | |
| SCHEMBL2596888 | 0.72 | NPC1 (0.44) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586198-B | Bromobenzoxazines method for synthesizing compound | 南开大学 | 2024-10-25 | — | — | CN | claimed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | claimed |
| CN-117586198-B | Bromobenzoxazines method for synthesizing compound | 南开大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-117586198-B | Bromobenzoxazines method for synthesizing compound | 南开大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586198-A | Synthesis method of bromobenzoxazine compound | 南开大学 | 2024-02-23 | — | — | CN | disclosed |
| CN-110770213-B | Sulfurized benzoxazines for use in the synthesis of polybenzoxazines | 米其林集团总公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-110770314-B | Metal or metallized reinforcement having a surface coated with a cured polybenzoxazine | 米其林集团总公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-110770213-A | Sulfurized benzoxazines for use in the synthesis of polybenzoxazines | 米其林集团总公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-110770314-A | Metal or metallized reinforcement having a surface coated with a cured polybenzoxazine | 米其林集团总公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-1458392-B9 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1458392-A4 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | ABL1, LCK, SRC | MAOA 747/4885MAOB 663/4885OXTR 3729/4885 |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | MAOA 182/4885MAOB 101/4885OXTR 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.